Patients with recurrent miscarriage (RM) show up-regulated cytotoxic natural killer (NK) cells that are suspected to play a causal role in abortion. In the present study, we investigated counter-regulating inhibitory mechanisms and compared the results in RM patients with those of healthy controls (HC), patients with end-stage renal disease (ESRD) and kidney transplant recipients late post-transplant (TX). NK, NK T and T cell subsets were analysed in the peripheral blood of 31 RM, 14 female ESRD and nine female TX patients as well as 21 female HC using eight-colour fluorescence flow cytometry. Compared with HC, RM patients showed significantly higher absolute numbers of CD56 
Summary
Patients with recurrent miscarriage (RM) show up-regulated cytotoxic natural killer (NK) cells that are suspected to play a causal role in abortion.
In the present study, we investigated counter-regulating inhibitory mechanisms and compared the results in RM patients with those of healthy controls (HC), patients with end-stage renal disease (ESRD) and kidney transplant recipients late post-transplant (TX). NK, NK T and T cell subsets were analysed in the peripheral blood of 31 RM, 14 female ESRD and nine female TX patients as well as 21 female HC using eight-colour fluorescence flow cytometry. Compared with HC, RM patients showed significantly higher absolute numbers of CD56 
Introduction
Natural killer (NK) cells represent a pool of heterogeneous innate lymphoid cells with a primarily cytotoxic function. They produce interferon (IFN)-g, perforin and granzyme [1] . However, there is increasing evidence for immunoregulatory NK cells that might mediate immune responses by secretion of interleukin (IL)-10, IL-4 and transforming growth factor (TGF)-b and/or might be responsive to these particular cytokines [2] [3] [4] [5] . A robust reconstitution of immunoregulatory NK cells by day 14 after allogeneic stem cell transplantation is an important determinant of clinical outcome, and it has been suggested that NK cells may suppress the development of the T cell-mediated alloreactive immune response through production of IL-10 [4] . In a co-culture system, the interaction between macrophages and endometrial stromal cells was shown to down-regulate cytotoxicity of NK cells, possibly by stimulating the secretion of IL-10 and TGF-b [6] . Recent evidence provides support for the notion that natural killer T (NK T) cells (a small but important immunoregulatory T cell subset of human peripheral blood lymphocytes) play a pivotal role in pregnancy [7] . NK T cells with unique transcriptional and cytokine profiles exist in different peripheral tissues, acting as mediators between the innate and adaptive immune systems. NK T cells secrete IL-4 and IFN-g, which might regulate the balance between T helper type 1 (Th1) and Th2 responses [7] . Furthermore, an increased number of circulating human leucocyte antigen (HLA)-G 1 , IL-10 1 and TGF-b 1 NK cells was demonstrated in breast cancer patients, suggesting that they might impair anti-tumour immunity [5] . During pregnancy there is an increased infiltration of immunoregulatory NK cells in the uterus (uterine NK cells) that supports pregnancy [8] . In a previous study, we were able to demonstrate abnormally low IL-10 1 NK and abnormally high cytotoxic NK cells in the blood of patients with recurrent miscarriage (RM) [9] . In the same study, we also investigated patients with end-stage renal disease (ESRD) and renal transplant recipients late posttransplant receiving low dose immunosuppression. ESRD and transplant patients are exposed long-term to auto-(glomerulonephritis, diabetes, rheumatism, etc.) and alloantigen (blood transfusions, donor antigens on the graft), providing a permanent stimulus for the immune system. The immune system of RM patients is also permanently stimulated. It has been shown that pregnant women develop microchimerism, with fetal progenitor cells circulating for many decades [10] , and we speculate that this might also happen in RM patients. Interestingly, in our previous study ESRD and transplant recipients late posttransplant showed lower cytotoxic NK cells and transplant recipients late post-transplant showed significantly higher IL-10 1 CD56 bright NK cells than RM patients [9] . High cytotoxic NK cells were found to be associated with impaired graft function, whereas high IL-10 1 CD56 bright NK cells were associated with good kidney transplant outcome [9] . Our observation of increased cytotoxic NK cells in patients with RM [9] agrees with reports of others [11, 12] . In the present study we investigated additional NK cell subsets. Our focus was upon NK cells, NK T cells and T cells that produce IL-4 and/or TGF-b and/or co-express the inhibitory surface receptors CD158a (KIR2DL1), CD158b (KIR2DL2/L3), CD158e (KIR3DL1) and/or NKG2A and/or the stimulating receptor NKG2D. An up-regulation of inhibiting and stimulating NKG2 receptors was observed after allogeneic or autologous haematopoietic stem cell transplantation and in patients with rheumatoid arthritis, whereby a gene polymorphism of NKG2 was found to be associated with susceptibility and severity of rheumatoid arthritis [13] [14] [15] . Certain CD158 determinants summarized as killer cell immunoglobulin-like receptors (KIR) were found to be associated with RM [16] [17] [18] [19] as well as control of viral infection, chronic rejection and graft loss in renal transplantation [20, 21] .
All RM patients studied by us were 3-12 months after abortion and untreated. In the first step of our approach, we identified cell subsets whose absolute numbers were different in RM patients and female healthy controls (HC). Next, we analysed whether numbers of these cell subsets were also different from those of female transplant recipients late post-transplant and female ESRD patients. In transplant recipients we also investigated whether particular cell subsets were associated with graft outcome. We speculated that cell subsets that were involved in graft outcome in transplant recipients might have similar immunological stimulatory or inhibitory effects in RM patients. Our goal was the identification of NK, NK T and T cell subsets that might have clinical relevance in patients with RM and kidney transplant recipients. ESRD patients were analysed in addition to HC in order to obtain comparative data in a patient population with similar disease history as transplant recipients, but without immunosuppressive therapy. Our expectation was that RM patients would show up-regulated inhibitory mechanisms, in contrast to transplant recipients and ESRD patients in whom we expected normal or down-regulated inhibitory mechanisms. We hypothesized that RM patients are unable to form a balance of cytotoxic and inhibitory cell subsets that support pregnancy with live birth. Consequently, RM patients should show higher inhibitory cell subsets than female HC.
Methods

Patients and healthy controls
All patients and controls gave informed consent for the tests performed, and the study was approved by the Heidelberg ethical committee (S-225/2014). The study was conducted in adherence to the Declaration of Helsinki. All participants provided their written informed consent to participate in this study. The consent procedure was approved by the local ethics committee. Laboratory staff and healthy blood donors served as HC. Blood from transplant patients was obtained during regular visits to the out-patient clinics of the university hospitals in Heidelberg and Giessen. Demographic data of the patients are summarized in Table 1 . Transplant patients received combinations of cyclosporin, tacrolimus, steroids and mycophenolate mofetil as immunosuppressive treatment. Blood from RM patients was obtained during visits to the outpatient clinic of the university hospital in Heidelberg. Patients had a history of three or more consecutive miscarriages. Non-pregnant RM patients were screened routinely for (i) anatomical disorders by vaginal ultrasound and hysteroscopy; (ii) endocrinological dysfunctions [polycystic ovary syndrome according to the Rotterdam criteria, hyperprolactinaemia, hyperandrogenaemia, insufficiency of the corpus-luteum and thyroidal dysfunctions (hypo-/ hyperthyreosis, thyroid autoantibodies)]; (iii) autoimmunological disorders [anti-nuclear antibodies > 1 : 160, anticardiolipin antibodies: immunoglobulin (Ig)G and IgM, anti-b2-glycoprotein IgG and IgM or lupus anti-coagulant]; (iv) deficiencies in coagulation factors (protein C, protein S, factor XII, or anti-thrombin); (v) inherited haemostatic changes [genetic analyses factor V, prothrombin and methylenetetrahydrofolate reductase (MTHFR genotype]; and (vi) fetal and parental chromosomal disorders (numerical aberrations). All analyses as well as cell determinations were performed at least 3 months after the last pregnancy. We studied 31 patients with idiopathic RM.
Immunostaining for flow cytometry and quantifications of NK, NK T and T cell subsets
Freshly drawn blood samples were analysed immediately after arrival in the laboratory. First, 150 ml of peripheral blood from each donor was incubated with fluorochrome-labelled monoclonal antibody against CD45/V500 (clone HI30), CD16/BV421 (clone 3G8), CD56/peridinin chlorophyll-cyanin 5Á5 (PerCP-Cy5Á5; clone B159), CD3/allophycocyanin H7 (APC-H7 (clone SK7) and HLA-DR/fluorescein isothiocyanate (FITC) (clone L243) or HLA-DR/phycoerythrin (PE; clone 3G8) in each tube, whereas antibody against CD158a/PE (clone REA284, KIR2DL1), CD158b/APC (clone DX27, KIR2DL2/L3), CD158e/APC (clone DX9, KIR3DL1), NKG2A/APC (clone REA110), NKG2D/BB515 (clone 1D11), IFN-gR/PE (clone GIR-208), CD25/APC (clone M-A251), CD69/PE (clone FN50), TGF-bRII/PE (polyclonal), CD210a (IL-10R)/Alexa Fluor 647 (clone 3F9) and IgG-isotype controls were added only to certain tubes. All tubes were vortexed briefly and incubated in the dark at room temperature for 30 min. Secondly, 2 ml of 1 3 fluorescence activated cell sorter (FACS) lysing solution (BD Bioscience, Heidelberg, Germany) was added to all tubes. The tubes were vortexed again, incubated in the dark at room temperature for 10 min and the cells were washed twice with 2 ml phosphate-buffered saline (PBS). Tubes containing only surface markers were resuspended with 300 ml PBS and thereafter ready for measurement. When intracellular proteins were analysed, cells were permeabilized after staining with surface markers and lysed. Surface-stained cells from each sample were treated with 500 ml of 1 3 BD Perm/Wash buffer II (BD Bioscience) for 10 min after the lysing process and last wash. The cells were washed with 2 ml PBS and resuspended in 100 ml PBS. Antibody against intracellular determinants such as anti-TGF-b1/APC (clone 27232; R&D Systems, Inc., Minneapolis, MN, USA), anti-IL-4/PE (clone MP4-25D2, BD Bioscience), anti-IL-10/PE (clone JES3-19F1, BD Bioscience, Germany), anti-IFN-g/APC (clone B27, BD Bioscience) and anti-IL-17/PE (clone SCPL1362) was added. After an incubation period of 30 min, cells were washed twice with PBS, resuspended with 300 ml PBS and were then ready for measurement.
All monoclonal antibodies and isotype controls were purchased from BD Bioscience, except anti-CD158a, antiCD158b, anti-CD158e, anti-NKG2A (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and anti-TGF-bRII and anti-TGF-b1 (R&D Systems, Inc.).
Samples were analysed using eight-colour fluorescence and a FACSCanto II triple-laser flow cytometer (BD Biosciences). At least 50 000 lymphocyte events were studied in the initial forward/side-scatter (FSC/SSC) dot-plot (see gating strategy in Fig. 1 ). Cells were not stimulated for intracellular staining of cytokines. Thus, our data reflect the cytokine production of NK, NK T and T cells in vivo.
Proportions of NK, NK T and T lymphocytes were determined using eight-colour flow cytometry. Each tube contained anti-CD45 monoclonal antibody. Absolute counts of CD45 lymphocytes were determined in the blood of each individual using Trucount tubes (BD Bioscience). Absolute numbers of NK, NK T and T lymphocyte subsets were calculated by comparing event numbers of cell subsets with the event number of CD45
1 lymphocytes in the test tube and the absolute cell number of CD45 1 lymphocytes in the Trucount tube.
Results
Strong expression of IL-4, TGF-b and IFN-g in NK cells from RM patients
We analysed CD3 -
CD56
1 and CD56 dim CD16 1 NK cell subsets in RM patients and female HC and found abnormally increased absolute numbers of NK cells subsets expressing IL-4, TGF-b and/or IFN-g in RM patients. RM patients showed higher CD3 -CD56 1 (P 5 0Á002) NK cells, representing the total NK cell pool, and higher absolute numbers of the major NK cell subset CD56 dim CD16 1 (P 5 0Á002) than female HC ( 1 NK cells with IL-4 (for both P < 0Á001), TGFb (P 5 0Á018 and P 5 0Á017) and/or IFN-g (for both P 5 0Á011) production than female HC. In addition, RM patients showed higher CD3 -
1 NK cells with the phe-
female HC (Table 2) . With respect to the small CD56 bright NK cell subset, RM patients showed more IL-17 1 CD56
bright NK cells (P 5 0Á028) than female HC (Table 2) . When the same cell subsets were analysed in female kidney recipients late post-transplant and female ESRD patients, patients and female HC had similar absolute numbers of cells subsets [P 5 not significant (n.s.)] ( Table 2) .
The data indicate increased numbers of NK cells producing IL-4, TGF-b and/or IFN-g in RM patients and normal levels of these NK cell subsets in transplant recipients late post-transplant, as well as ESRD patients.
Increased CD158
1 and NKG2 1 NK cells in RM patients 1 NK cells expressing CD158 and NKG2 receptors than female HC. They showed higher absolute numbers of CD158a 1 (P 5 0Á047), CD158b
1 NK cells and higher CD158a 1 (P 5 0Á045), (Table 2 ). Female ESRD patients had normal levels of these NK cell subsets (versus HC: P 5 n.s.) ( Table 2 ). The data indicate abnormally increased CD158a 
Increased NK T cell subsets in RM patients
RM patients showed abnormally increased NK T cells expressing IFN-g, IL-4, TGF-b, CD158a and CD158e. They had higher CD3 1 CD56 1 NK T cells with the phenotype
) and CD158a -CD158e 1 (P 5 0Á027) than female HC (Table 2 ).
In contrast, female transplant recipients late posttransplant and female ESRD patients had normal levels of these NK T cell subsets (versus HC: P 5 n.s.), suggesting increased levels of NK T cells with inhibitory CD158 receptors and inhibitory cytokines in RM patients but normal levels of these cells in female ESRD and transplant patients ( Table 2 ).
Increased T cell subsets in RM patients
RM patients had higher T cells with inhibitory cytokines and inhibitory KIRs. RM patients showed higher IL-4
-(P 5 0Á016) and CD69 1 (P 5 0Á049) T cells than female HC (Table 2) . In female ESRD patients and female kidney transplant recipients late post-transplant, all T cell subsets mentioned above were similar to those of female HC (P 5 n.s.), with the exception of higher CD69 1 (P 5 0Á033 and P 5 0Á025, respectively) T cells in ESRD patients and kidney transplant recipients late post-transplant ( Table 2 ).
The data indicate increased levels of T cells with inhibitory cytokines, inhibitory CD158e and activating NKG2D receptors in patients with RM, but normal levels of these T cell subsets in female ESRD patients and female kidney transplant recipients late post-transplant.
NK, NK T and T cell subsets and graft function
Of all NK, NK T and T cell subsets whose absolute counts were increased abnormally in RM patients, only high NKG2D
1 NKG2A -and NKG2D 1 T cells (serum creatinine:
r 5 -0Á410, P 5 0Á034 and r 5 -0Á435, P 5 0Á023, respectively) and low NKG2D -NKG2A r 5 -0Á437, P 5 0Á023 and r 5 -0Á388, P 5 0Á046, respectively] were associated with good graft function, suggesting an association of T cells expressing activating NKG2D and lacking inhibitory NKG2A receptors with good long-term kidney graft function (Fig. 2 ).
Statistical analysis of NK, NK T and T cell proportions
In addition to the absolute counts of NK, NK T and T cells, we analysed relative numbers of these cells. recipients. Importantly, NKG2D expression on NK as well as T cells was associated with good graft function in transplant recipients, whereas NKG2A expression was associated with impaired long-term graft function (Fig. 2) .
Stochasticity of CD158 and NKG2 cell receptors
Recent data suggest that single, double and triple inhibitory KIRs are expressed by NK cells with decreasing incidence [22, 23] . female patients and female HC. The most important finding was that most of the RM patients, female HC, female kidney graft recipients and female ESRD patients showed CD56 1 CD16 1 NK cells co-expressing the combination of CD158a, CD158b, CD158e and NKG2A as well as NKG2D (Fig. 3a) . Interestingly, this phenotype was more common in RM patients than in female HC and female transplant recipients late post-transplant (v 2 test, CD158a/b/ e
111
NKG2A
1 NKG2D 1 CD56 1 CD16 1 NK cells in RM versus female HC or female late post-transplant: P < 0Á05), supporting the hypothesis that RM patients have an abnormal up-regulation of inhibitory KIR and NKG2A receptors that is not observed in female HC and female graft recipients late post-transplant. In contrast, KIR and NKG2 patterns on NK T and T cells were similar among the different groups of patients and HC (Fig. 3b,c) .
Discussion
We have reported previously that RM patients had higher cytotoxic perforin 1 NK cells than HC, whereas kidney transplant recipients late post-transplant had lower perforin 1 NK cells [9] . Moreover, potentially immunoregulatory IL-10 1
CD56
bright NK cells were significantly higher in renal transplant recipients late post-transplant than in RM patients. In the present study, in the same patients we investigated additional potentially immunoregulatory NK cell subsets producing IL-4, TGF-b and IFN-g and expressing the corresponding cytokine receptors on the cell surface. Furthermore, we addressed the expression of activating and inhibitory CD158 and NKG2 receptors on NK, NK T and T cell subsets in the different patient groups.
In a first approach of our statistical analysis, we selected the parameters that were statistically different between RM patients and female HC. In the second step of our analysis, we compared blood levels of these selected parameters with those in female ESRD patients and female patients late post-transplant (Table 2) . To our knowledge, this is the first study that compares NK cell subsets of patients with recurrent miscarriage with those of patients after successful renal transplantation and HC, with the aim of identifying NK cell subsets that might contribute to pathogenesis and outcome. One would expect that a particular NK cell subset with certain qualities should have similar function in RM patients, transplant recipients and HC.
Our data show that RM patients possess abnormally high NK, NK T and T lymphocyte subsets that produce immunosuppressive IL-4 and TGF-b, as well as immunostimulatory IFN-g, whereas successful kidney transplant recipients have normal counts of these cell subsets in the blood. We interpret the increased numbers as an indication of an activated immune system in RM patients, showing up-regulation of immunostimulatory as well as immunoregulatory components. The observation of an up-regulated immune system in RM patients is in line with our previous All data are given as mean 6 standard deviation. Statistical analysis was performed using Spearman's rank correlation test. P-values of < 0Á05 were marked by yellow and correlations of < 0Á01 by orange backgrounds. Table 3 summarizes proportions of all cell subsets that were listed in publications, in which we showed that RM patients have increased absolute numbers of activated CD4 1 and CD8
1
T lymphocytes and NK cells expressing CD16 and/or CD56 [24, 25] . In the present study, RM patients showed, in addition, increased absolute numbers of NK cell subsets expressing inhibitory CD158a, CD158b, CD158e and/or NKG2A receptors and/or stimulating NKG2D determinants on the cell surface. Moreover, RM patients showed CD56 1 CD16 1 NK cells co-expressing more frequently the combination of CD158a, CD158b, CD158e, NKG2A as well as NKG2D than female HC and female transplant recipients late post-transplant, supporting the hypothesis that RM patients have an abnormal up-regulation of inhibitory KIR and NKG2A receptors that is not observed in female HC and female graft recipients late post-transplant. Furthermore, RM patients exhibited increased absolute counts of potentially inhibitory NK T cells with CD158a and/or CD158e, TGF-b and/or IL-4 and higher levels of T cells that expressed potentially inhibitory CD158e and/or IL-4 as well as stimulating NKG2D and the early activation antigen CD69. Our previous findings showed that RM patients possess strongly activated cytotoxic NK cells [9] , and our present data suggest that these activated cytotoxic NK cells are capable of inducing a potentially counter-regulatory immune response consisting of inhibitory NK, NK T and T cells detectable in the blood of RM patients. Our findings agree with the observations of Perricone et al. and Ota et al., who demonstrated increased NK cell numbers in RM patients with strong activation and cytotoxicity of NK cells [11, 26] . Ntrivalas et al. described that CD158a and CD158b inhibitory receptor expression by CD56 dim CD16 [19] . In our study, RM patients showed abnormally high levels of NK, NK T and T cells with inhibitory signals, whereas ESRD patients as well as transplant recipients late post-transplant showed normal absolute numbers of these cell subsets, suggesting that the immune system in these patients was in balance and was unbalanced in RM patients. We interpret our data to show that RM patients try to down-regulate their activated cytotoxic immune system by the induction of inhibitory mechanisms. Because male fetal progenitor cells have been shown to persist in maternal blood for as long as 27 years postpartum, the antigen initiating the cytotoxic and subsequently the inhibitory immune response can persist in these patients [10] . Establishment of immunological balance takes time and represents an active process, involving several compartments of immune cells, such as NK, NK T and T cells. Our finding of an association of high activating NKG2D
1 and low inhibitory NKG2A 1 NK, NK T and T cells with good longterm graft function in transplant recipients points towards that direction. We would assume that NK, NK T and T cells with activating NKG2D initiate the development of an immune balance that is favourable for the transplant patient. We speculate that the immune system in transplant patients with chronic antigen exposure and a stable clinical course (no rejection, no infection, no florid inflammation of the own kidneys) is down-regulated successfully with time, resulting in low or normal levels of cytotoxic and inhibitory NK cells. In contrast, RM patients appear to be unable to form this normal balance of cytotoxic and inhibitory cell subsets, and this imbalance may result in recurrent miscarriage. Conceivably, IL-10 1 CD56 bright NK cells are involved in the successful establishment of the immune balance because their absolute and relative counts were higher in transplant recipients than in RM patients, and absolute and relative counts were associated with good long-term kidney graft function [9] . We hypothesize that the posttransplant increase of this cell subset [9] contributes to long-term suppression of the immune system and enables the tapering of immunosuppressive drugs in transplant recipients with good long-term graft outcome.
We hypothesize that RM patients undergo chronic stimulation by paternal antigen on fetal cells that persists in the form of microchimerism. In the 1990s it was discussed whether microchimerism is necessary for tolerance induction in organ transplantation. Starzl postulated that microchimerism detected 27-29 years after successful kidney transplantation is a seminal event that defines graft acceptance and can lead ultimately to acquired donor-specific non-responsiveness (tolerance) [29] . In contrast, Schlitt reported that microchimerism is not necessary for achieving a state of tolerance, but may be a promising clinical approach for tolerance induction [30] . We hypothesize that RM patients show long-term microchimerism similar to women after delivery and patients after transplantation. Chimeric cells are not rejected, but they do not induce tolerance against paternal HLA antigens because clinical experience has shown that, without immunosuppression, the mother rejects a kidney transplant from her child. In women after successful pregnancy, chimeric cells do not induce an immune response because fertile women showed lower NK cell numbers than RM patients [31] . Moreover, early pregnant women had higher IL-10-producing NKr1 cells than non-pregnant women, and the number of these cells decreased further in RM patients [32] . We speculate that chimeric cells in RM patients represent a continuous stimulus for cytotoxic cells. As long as there is no successful down-regulation of the cytotoxic immune reaction and the counter-regulatory inhibitory response, successful pregnancy with live birth is not possible. IL-10-producing NK cells might modulate cytotoxic and inhibitory immune responses and might favour the establishment of a balance of the immune system.
Mor et al. reviewed the immunological aspects of pregnancy and described an initial proinflammatory stage at implantation and placentation followed by an antiinflammatory phase of fetal growth and a final switch back to a proinflammatory pattern that is necessary for delivery [33] . Our data suggest that RM patients fail to switch successfully to the anti-inflammatory stage that is necessary for down-regulation of the cytotoxic immune responses and formation of a microenvironment that is protective for the fetus. In our study, dysbalance of the immune system was detectable for at least 12 months after abortion and thus might contribute to further abortions. Female HC lack this imbalance, which underlines the abnormal character of the long-lasting up-regulation of cytotoxic as well as inhibitory immune mechanisms in RM patients.
Immunoregulatory NK cells show in part the phenotype CD56 dim CD16
, and this NK cell subset usually represents strongly cytotoxic NK cells [12] . Our data suggest that in transplant recipients and RM patients cytotoxic CD56 dim CD16 1 NK cells differentiate and obtain a phenotype of regulatory inhibitory NK cells. Immunoregulatory cell subsets were determined in the periphery. We speculate that differentiation of precursor or cytotoxic NK cells to immunoregulatory NK cells occurred at sites of alloantigen contact in combination with a micromilieu that supports this cell differentiation.
Conclusions
Our data show that RM patients have higher NK, NK T and T cells in the blood which express inhibitory cytokines and inhibitory surface receptors than female HC. In contrast, ESRD and long-term transplant patients have normal or even decreased levels of these NK, NK T and T cells, indicating a balanced immune system in ESRD patients without and in long-term transplant recipients with minimal immunosuppressive treatment. The up-regulation of inhibitory mechanisms in RM patients can be interpreted as showing counter-regulation to a strongly up-regulated cytotoxic immune system. This may play a causal role in RM. We believe that RM patients are unable to form the balance of cytotoxic and inhibitory cell subsets that is required for pregnancy with live birth. Successful inhibition of the cytotoxic immune response might be a therapeutic option that should be studied in clinical trials.
